Skip to main content

Table 3 Crude and adjusted rate ratios for the risk of aortic aneurysm with oral antidiabetic drugs

From: Association between use of oral-antidiabetic drugs and the risk of aortic aneurysm: a nested case–control analysis

Dosage

No. (%)

Odds ratio (95 % CI)

Cases (n = 4468)

Control (n = 4468)

Crude

p value

Adjusteda

p value

No metformin useb

2882

2455

1 [Reference]

 

1 [Reference]

 

Metformin use (daysc)

1586

2013

0.64 (0.58–0.70)

<0.001

0.72 (0.64–0.80)

<0.001

 Quantile 1 (11, 6–17)

364

363

0.85 (0.73–0.99)

0.042

0.91 (0.78–1.08)

0.291

 Quantile 2 (56, 41–79)

326

400

0.66 (0.56–0.77)

<0.001

0.71 (0.60–0.85)

<0.001

 Quantile 3 (181, 139–233)

303

404

0.60 (0.51–0.70)

<0.001

0.67 (0.56–0.81)

<0.001

 Quantile 4 (459, 375–576)

316

404

0.60 (0.50–0.71)

<0.001

0.70 (0.58–0.86)

0.001

 Quantile 5 (1127, 861–1666)

277

442

0.46 (0.38–0.55)

<0.001

0.57 (0.45–0.72)

<0.001

No DPP-4 inhibitor useb

4305

4281

1 [Reference]

 

1 [Reference]

 

DPP-4 use (daysc)

163

187

0.85 (0.68–1.07)

0.168

1.07 (0.84–1.36)

0.582

 Quantile 1 (25, 14–30)

45

28

1.58 (0.98–2.55)

0.062

1.99 (1.20–3.29)

0.007

 Quantile 2 (70, 56–84)

28

39

0.70 (0.43–1.15)

0.157

0.96 (0.57–1.62)

0.884

 Quantile 3 (140, 112–168)

31

40

0.74 (0.46–1.20)

0.224

1.00 (0.61–1.65)

0.992

 Quantile 4 (238, 210–273)

30

39

0.75 (0.46–1.22)

0.249

1.03 (0.62–1.72)

0.904

 Quantile 5 (509, 413–672)

29

41

0.70 (0.43–1.13)

0.143

1.01 (0.60–1.68)

0.978

No sulfonylurea useb

2779

2412

1 [Reference]

 

1 [Reference]

 

Sulfonylurea use (daysc)

1689

2056

0.68 (0.62–0.75)

<0.001

0.82 (0.74–0.92)

0.001

 Quantile 1 (20, 9–37)

402

359

0.96 (0.83–1.12)

0.624

1.04 (0.88–1.23)

0.630

 Quantile 2 (120, 84–165)

336

401

0.70 (0.60–0.82)

<0.001

0.81 (0.69–0.97)

0.018

 Quantile 3 (424, 313–544)

336

413

0.67 (0.57–0.79)

<0.001

0.79 (0.66–0.95)

0.010

 Quantile 4 (1128, 881–1408)

312

437

0.55 (0.47–0.65)

<0.001

0.71 (0.59–0.87)

0.001

 Quantile 5 (3164, 2329–4620)

303

446

0.51 (0.43–0.61)

<0.001

0.74 (0.59–0.94)

0.014

No alpha-glucosidase inhibitors useb

4077

3999

1 [Reference]

 

1 [Reference]

 

Alpha-glucosidase inhibitors use (daysc)

391

469

0.81 (0.70–0.93)

0.004

0.95 (0.81–1.11)

0.507

 Quantile 1 (7, 5–10)

83

108

0.75 (0.56–1.00)

0.050

0.89 (0.66–1.21)

0.463

 Quantile 2 (28, 19–35)

79

77

0.99 (0.72–1.36)

0.948

1.14 (0.82–1.59)

0.448

 Quantile 3 (68, 56–85)

81

88

0.89 (0.66–1.22)

0.477

1.04 (0.76–1.44)

0.793

 Quantile 4 (164, 134–210)

79

93

0.83 (0.61–1.12)

0.212

1.03 (0.75–1.42)

0.861

 Quantile 5 (444, 344–630)

69

103

0.63 (0.45–0.87)

0.005

0.87 (0.61–1.23)

0.423

No thiazolidinedione useb

4171

4065

1 [Reference]

 

1 [Reference]

 

Thiazolidinedione use (daysc)

297

403

0.70 (0.59–0.82)

<0.001

0.82 (0.69–0.98)

0.003

 Quantile 1 (19, 13–28)

71

69

0.97 (0.70–1.36)

0.873

1.12 (0.79–1.59)

0.518

 Quantile 2 (65, 56–84)

54

86

0.58 (0.41–0.83)

0.003

0.77 (0.53–1.12)

0.167

 Quantile 3 (206, 168–266)

54

87

0.59 (0.42–0.84)

0.003

0.77 (0.53–1.11)

0.164

 Quantile 4 (532, 413–630)

65

74

0.83 (0.59–1.16)

0.281

1.14 (0.79–1.63)

0.485

 Quantile 5 (1247, 977–1980)

53

87

0.57 (0.40–0.81)

0.002

0.80 (0.54–1.17)

0.241

  1. aAdjusted for using alpha blocker, ACE inhibitor or ARB, beta blocker, calcium channel blocker, diuretics, antiplatelet agent, warfarin, statin, steroid, antidepressants, NSAID, and insulin
  2. bUse of one prescription at any time prior to the index date
  3. cMedians, interquartile range
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840